双膦酸盐治疗绝经后骨质疏松的系统评价再评价

发布时间：2018-01-20 09:06

本文关键词： 双膦酸盐绝经后骨质疏松间接比较系统评价再评价 Meta分析　出处：《中国临床药理学杂志》2016年06期 　论文类型：期刊论文

【摘要】：目的系统评价再评价并对比双膦酸盐治疗绝经后骨质疏松的有效性。方法计算机检索Cochrane Library、Pub Med、SCI、中国知网(CNKI)、维普数据库(VIP)、中国生物医学文献数据库(CBM)及万方数据库,并进行手工检索,筛选符合的双膦酸盐治疗绝经后骨质疏松的系统评价,用AMSTAR量表评价文献质量,用Rev Man5.3软件进行Meta分析,再用间接比较方法进行结果分析。结果纳入12篇系统评价,共6种双膦酸盐药物(唑来膦酸、依替膦酸、阿仑膦酸、伊班膦酸、利噻膦酸和帕米膦酸)。纳入文献的AMSTAR量表质量评分均较高。Meta分析结果显示,5种双膦酸盐(帕米膦酸除外)治疗绝经后骨质疏松疗效显著。间接比较结果显示,唑来膦酸与安慰剂、利噻膦酸、伊班膦酸、阿仑膦酸、依替膦酸比较,降低椎骨骨折发生率的相对危险度(RR)分别为0.31,0.49,0.53,0.57,0.74;唑来膦酸与安慰剂、利噻膦酸、伊班膦酸、阿仑膦酸、依替膦酸比较,降低非椎骨骨折发生率的RR值分别为0.72,0.71,0.89,0.87,0.90。结论唑来膦酸在这5种双膦酸盐中治疗绝经后骨质疏松的疗效最好。
[Abstract]:Objective to evaluate and compare the efficacy of bisphosphonates in the treatment of postmenopausal osteoporosis. Methods Cochrane Library Pub Medsci was searched by computer. CNKI, Weipu database, CBM and Wanfang database were searched by hand. A systematic evaluation of bisphosphonates for the treatment of postmenopausal osteoporosis was carried out. The literature quality was evaluated with AMSTAR scale and Meta analysis was performed with Rev Man5.3 software. The results were analyzed by indirect comparison method. The results were analyzed by 12 systematic evaluations. There were 6 kinds of bisphosphonates (zoledronic acid, etylphosphonic acid, alendronic acid, ibandronic acid). The results of meta-analysis showed that the quality scores of AMSTAR scale included in the literature were higher. Five kinds of bisphosphonates (except pamiphosphonic acid) were effective in the treatment of postmenopausal osteoporosis. Indirect comparison showed that zoledronic acid was compared with placebo, lithiophosphonic acid, ibandronic acid, alendronic acid and etedronic acid. The relative risk (RR) of reducing the incidence of vertebral fracture was 0.31 ~ 0.49 ~ 0.53 ~ 0.57 ~ 0.74; The RR of zoledronic acid in comparison with placebo, ritimronic acid, ibandronic acid, alendronic acid and etedronic acid to reduce the incidence of non-vertebral fracture was 0.72 卤0.71 卤0.87, respectively. Conclusion Zoledronic acid is the best in the treatment of postmenopausal osteoporosis.
【作者单位】：暨南大学药学院;
【基金】：暨南大学大学生创新创业训练计划基金资助项目(1055914104)
【分类号】：R580
【正文快照】： LUO Chu-jun,LI Min-juan,ZHONG Dai-yun,ZHANG Jian-ping(College of Pharmacy,Jinan University,Guangzhou 510632,China)绝经后骨质疏松症(PMO)一般发生在妇女绝经后5~10年内[1],双膦酸盐一直都是国内外治疗绝经后骨质疏松的一线药物。系统评价再评价是指全面收集同一疾病

【相似文献】